Overview

The Gene Technology Act 2000 was enacted to regulate the handling, storage, use, and disposal of genetically modified organisms, including gene technology that involves human clinical trials. This legislation was introduced to address the need for stringent oversight and regulation of activities that involve genetically modified organisms, ensuring that they do not pose a risk to human health or the environment. The Act is overseen by the Office of the Gene Technology Regulator, whose policy objective is to protect human health and safety and the environment while facilitating the benefits of gene technology. In this instance, the Regulator is seeking public feedback on an application by Novotech (Australia) Pty Limited to conduct a clinical trial of a genetically modified Vaccinia virus based treatment for solid cancerous tumours. This application has been assessed against the criteria set out in the Gene Technology Act 2000, and the Regulator is now inviting submissions on the Risk Assessment and Risk Management Plan prepared for this application.

Scope and Application

This legislation pertains to the clinical trial application by Novotech (Australia) Pty Limited to conduct a controlled trial of a genetically modified Vaccinia virus based treatment for solid cancerous tumours in Australia. The application is assessed by the Gene Technology Regulator, and the scope of the Act applies to the proposed trial participants, clinical trial sites, and hospitals involved in the trial within Australia. The legislation also encompasses the protection of human health and safety and the environment in relation to this trial, with a specific focus on the risk assessment and risk management plan prepared by the Regulator. The Act operates on a national level, as it involves the regulation of a clinical trial under the Commonwealth jurisdiction, and extends its reach to all relevant sites within Australia. There are no explicit exclusions or exemptions mentioned in the text, and the application is subject to written submissions from interested parties before the Regulator makes a decision on issuing the licence. The Act may be further extended or restricted through subordinate instruments that are not detailed in the provided text.

Key Provisions

The main sections of the Gazette C2021G00057 concern the assessment of a clinical trial application by Novotech (Australia) Pty Limited to trial a genetically modified Vaccinia virus based treatment for solid cancerous tumours (sections 1 and 2). Section 1 specifies the scope of the proposed clinical trial, detailing the number of participants (up to 150), the duration (5 years), and the locations (clinical trial sites and hospitals in Australia). Section 2 outlines the preparation of a Risk Assessment and Risk Management Plan (RARMP) by the Gene Technology Regulator to evaluate the potential risks to human health and safety and the environment associated with the trial. The obligations imposed on the parties governed by this Act include the preparation and submission of a comprehensive RARMP by the Gene Technology Regulator, as well as the requirement for Novotech (Australia) Pty Limited to conduct the clinical trial under limited and controlled conditions (sections 1 and 2). Additionally, the Act mandates that the Regulator welcomes written submissions on the trial from interested parties, specifically referencing human health and safety and environmental concerns (section 3). Submissions must be made in reference to DIR 179 and should be received by the specified deadline of 24 February 2021. The Gazette C2021G00057 does not explicitly mention any offences, penalties, or consequences for breach within the provided text. However, the Act implies that failure to comply with the requirements for the clinical trial, such as not adhering to the stipulated conditions or not submitting required documentation, could result in the Regulator denying the licence to conduct the trial. Additionally, non-compliance with the regulatory process or failure to address identified risks could potentially lead to legal consequences under other relevant legislation governing clinical trials and gene technology in Australia.